HUP0400475A3 - Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof - Google Patents
Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereofInfo
- Publication number
- HUP0400475A3 HUP0400475A3 HU0400475A HUP0400475A HUP0400475A3 HU P0400475 A3 HUP0400475 A3 HU P0400475A3 HU 0400475 A HU0400475 A HU 0400475A HU P0400475 A HUP0400475 A HU P0400475A HU P0400475 A3 HUP0400475 A3 HU P0400475A3
- Authority
- HU
- Hungary
- Prior art keywords
- hmg
- pharmaceutical compositions
- compositions containing
- receptor antagonist
- compounds selected
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title 1
- 229940123934 Reductase inhibitor Drugs 0.000 title 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19674300P | 2000-04-12 | 2000-04-12 | |
PCT/EP2001/004115 WO2001076573A2 (en) | 2000-04-12 | 2001-04-10 | Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400475A2 HUP0400475A2 (hu) | 2004-06-28 |
HUP0400475A3 true HUP0400475A3 (en) | 2006-02-28 |
Family
ID=22726659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400475A HUP0400475A3 (en) | 2000-04-12 | 2001-04-10 | Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof |
Country Status (20)
Country | Link |
---|---|
US (2) | US20040023840A1 (hu) |
EP (1) | EP1326604A2 (hu) |
JP (1) | JP2003530342A (hu) |
KR (1) | KR20020089433A (hu) |
CN (2) | CN1440283A (hu) |
AR (1) | AR032152A1 (hu) |
AU (1) | AU2001258323A1 (hu) |
BR (1) | BR0109966A (hu) |
CA (1) | CA2405793A1 (hu) |
CZ (1) | CZ20023381A3 (hu) |
HU (1) | HUP0400475A3 (hu) |
IL (1) | IL152079A0 (hu) |
MX (1) | MXPA02010090A (hu) |
NO (1) | NO20024921L (hu) |
PE (1) | PE20020229A1 (hu) |
PL (1) | PL365696A1 (hu) |
RU (1) | RU2298418C2 (hu) |
SK (1) | SK14642002A3 (hu) |
WO (1) | WO2001076573A2 (hu) |
ZA (1) | ZA200208203B (hu) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
BR0111868A (pt) * | 2000-06-22 | 2003-07-01 | Novartis Ag | Composições farmacêuticas |
US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
ATE511395T1 (de) * | 2001-04-19 | 2011-06-15 | Kowa Co | Mittel zur behandlung von glomerulopathie |
WO2003035039A1 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
WO2003043615A2 (de) * | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertoniebehandlung während der akuten phase des schlaganfalls |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
CN100438911C (zh) * | 2002-12-27 | 2008-12-03 | 武田药品工业株式会社 | 体重增加抑制剂 |
DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
DK1587584T3 (da) * | 2003-01-16 | 2007-09-24 | Boehringer Ingelheim Int | Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdomme |
DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
US9345671B2 (en) | 2003-04-28 | 2016-05-24 | Daiichi Sankyo Company, Limited | Adiponectin production enhancer |
WO2004096276A1 (ja) * | 2003-04-28 | 2004-11-11 | Sankyo Company, Limited | 糖取り込み能増強剤 |
EP2287166A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
AU2008201290B2 (en) * | 2003-09-26 | 2010-12-09 | Astrazeneca Uk Limited | Therapeutic treatment |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
CA2546793A1 (en) * | 2003-12-16 | 2005-06-30 | Novartis Ag | Use of stating for the treatment of metabolic syndrome |
ATE493973T1 (de) * | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
CN101052402A (zh) * | 2004-10-29 | 2007-10-10 | 兴和株式会社 | 肾小球疾病治疗剂 |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
WO2007088705A1 (ja) * | 2006-01-31 | 2007-08-09 | Kowa Co., Ltd. | 糖尿病治療剤 |
US8685952B2 (en) | 2006-01-31 | 2014-04-01 | Kowa Co., Ltd. | Method for the treatment of diabetes |
FR2911279B1 (fr) * | 2007-01-11 | 2009-03-06 | Servier Lab | Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale |
GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
RU2505297C1 (ru) * | 2012-11-21 | 2014-01-27 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | Средство для медикаментозной коррекции нарушений нитроксидергической системы |
ES2637276T3 (es) * | 2013-05-13 | 2017-10-11 | Macro Plastics, Inc. | Contenedor de envío que comprende un cierre de seguridad |
BR102013028883A2 (pt) * | 2013-11-08 | 2015-10-06 | Hypermarcas S A | forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica |
MD4412C1 (ro) * | 2014-08-29 | 2016-11-30 | Алёна ДУРНЯ | Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
EA034975B1 (ru) * | 2018-03-13 | 2020-04-13 | Владимир Александрович Горшков-Кантакузен | Способ лечения лабильной и пароксизмальной гипертензии |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981470A (en) * | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
MX9707683A (es) * | 1995-04-07 | 1997-12-31 | Novartis Ag | Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan. |
JPH11508894A (ja) * | 1995-06-30 | 1999-08-03 | メルク エンド カンパニー インコーポレーテッド | Ace阻害剤とaii拮抗薬を用いる腎疾患の治療方法 |
CA2250395C (en) * | 1996-03-29 | 2005-09-06 | Smithkline Beecham Corporation | Eprosartan dihydrate and a process for its production and formulation |
ATE283704T1 (de) * | 1996-07-15 | 2004-12-15 | Sankyo Co | Pharmazeutische zusammensetzungen enthaltend cs- 866 und insulinresistenz verbesserndem mitteln und deren verwendung zur behandlung von arteriosklerose und xanthom |
-
2001
- 2001-04-10 AR ARP010101697A patent/AR032152A1/es not_active Application Discontinuation
- 2001-04-10 CA CA002405793A patent/CA2405793A1/en not_active Abandoned
- 2001-04-10 HU HU0400475A patent/HUP0400475A3/hu unknown
- 2001-04-10 AU AU2001258323A patent/AU2001258323A1/en not_active Abandoned
- 2001-04-10 CZ CZ20023381A patent/CZ20023381A3/cs unknown
- 2001-04-10 RU RU2002129558/15A patent/RU2298418C2/ru not_active IP Right Cessation
- 2001-04-10 JP JP2001574091A patent/JP2003530342A/ja active Pending
- 2001-04-10 MX MXPA02010090A patent/MXPA02010090A/es active IP Right Grant
- 2001-04-10 SK SK1464-2002A patent/SK14642002A3/sk unknown
- 2001-04-10 WO PCT/EP2001/004115 patent/WO2001076573A2/en active Application Filing
- 2001-04-10 KR KR1020027013336A patent/KR20020089433A/ko not_active Application Discontinuation
- 2001-04-10 EP EP01931583A patent/EP1326604A2/en not_active Withdrawn
- 2001-04-10 BR BR0109966-3A patent/BR0109966A/pt not_active IP Right Cessation
- 2001-04-10 PE PE2001000327A patent/PE20020229A1/es not_active Application Discontinuation
- 2001-04-10 CN CN01807919A patent/CN1440283A/zh active Pending
- 2001-04-10 PL PL01365696A patent/PL365696A1/xx not_active Application Discontinuation
- 2001-04-10 US US10/257,559 patent/US20040023840A1/en not_active Abandoned
- 2001-04-10 IL IL15207901A patent/IL152079A0/xx unknown
- 2001-04-10 CN CNA2004101012182A patent/CN1651087A/zh active Pending
-
2002
- 2002-10-11 NO NO20024921A patent/NO20024921L/no not_active Application Discontinuation
- 2002-10-11 ZA ZA200208203A patent/ZA200208203B/en unknown
-
2006
- 2006-10-31 US US11/590,215 patent/US20070105894A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0109966A (pt) | 2003-08-05 |
CN1651087A (zh) | 2005-08-10 |
US20040023840A1 (en) | 2004-02-05 |
JP2003530342A (ja) | 2003-10-14 |
PL365696A1 (en) | 2005-01-10 |
AU2001258323A1 (en) | 2001-10-23 |
HUP0400475A2 (hu) | 2004-06-28 |
CA2405793A1 (en) | 2001-10-18 |
KR20020089433A (ko) | 2002-11-29 |
CN1440283A (zh) | 2003-09-03 |
SK14642002A3 (sk) | 2003-05-02 |
MXPA02010090A (es) | 2003-02-12 |
WO2001076573A2 (en) | 2001-10-18 |
AR032152A1 (es) | 2003-10-29 |
NO20024921L (no) | 2002-11-07 |
PE20020229A1 (es) | 2002-04-11 |
IL152079A0 (en) | 2003-05-29 |
CZ20023381A3 (cs) | 2003-02-12 |
EP1326604A2 (en) | 2003-07-16 |
RU2298418C2 (ru) | 2007-05-10 |
NO20024921D0 (no) | 2002-10-11 |
ZA200208203B (en) | 2003-11-07 |
WO2001076573A3 (en) | 2003-04-17 |
US20070105894A1 (en) | 2007-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400475A3 (en) | Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof | |
HUP0303083A3 (en) | Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use | |
HUP0400206A3 (en) | Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them | |
HUP0302412A3 (en) | Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same | |
HUP0301472A3 (en) | Carbamate caspase inhibitors and uses thereof and pharmaceutical compositions containing them | |
HUS1500068I1 (hu) | Dezacetiláz inhibitor hatású hidroxamát származékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0301005A3 (en) | Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use | |
HUP0302991A3 (en) | Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds | |
HUP0302485A3 (en) | Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them | |
HUP0300544A3 (en) | Pharmaceutical compositions containing integrin expression inhibitors | |
HK1200368A1 (en) | Pharmaceutical compositions comprising a hmg coa reductase inhibitor hmg coa | |
HUP0400327A3 (en) | Azole derivatives having metalloproteinase inhibitor effect pharmaceutical compositions containing them and their use | |
HUP0302922A3 (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them | |
HUP0402370A3 (en) | Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination | |
HUP0200602A3 (en) | Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use | |
HUP0303193A3 (en) | Phthalayinone-piperidino-derivatives as pde4 inhibitors and pharmaceutical compositions containing them | |
HUP0204340A3 (en) | Compositions for delivery of a cortisol antagonist and their use | |
HUP0400328A3 (en) | Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them | |
HK1071308A1 (en) | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | |
HUP0302160A3 (en) | Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors | |
HUP0302068A3 (en) | Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them | |
IL162325A0 (en) | Hiv integrase inhibitor compounds and pharmaceutical compositions containing the same | |
HUP0103382A2 (en) | Naaladase inhibitors useful as pharmaceutical compounds and compositions | |
HUP0400654A3 (en) | Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them | |
HUP0300332A3 (en) | New combination of a betablocker and a cholesterol-lowering agent and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |